Abstract
Increasing evidence suggests that μ opioid receptor (MOP) expression is altered during the development of and withdrawal from substance dependence. Although anti-MOP antibodies have been hypothesized to be useful for estimating MOP expression levels, inconsistent MOP molecular weights (MWs) have been reported in studies using anti-MOP antibodies. In the present study, we generated a new anti-MOP antibody (N38) against the 1-38 amino acid sequence of the mouse MOP N-terminus and conducted Western blot analysis with wildtype and MOP knockout brain lysates to determine the MWs of intrinsic MOP. The N38 antibody detected migrating bands with relative MWs of 60-67 kDa in the plasma membrane fraction isolated from wildtype brain, but not from the MOP knockout brain. These migrating bands exhibited semi-linear density in the range of 3-30 μg membrane proteins/lane. The N38 antibody may be useful for quantitatively detecting MOP.
Keywords: Knockout mice, μ opioid receptor, quantification, Western blot analysis, alcohol-dependent, chronic cocaine, downregulates MOP mRNA, immunohistochemistry, MOP binding, mRNA levels, MOP proteins
Current Neuropharmacology
Title: Quantitative Detection of μ Opioid Receptor: Western Blot Analyses Using µ Opioid Receptor Knockout Mice
Volume: 9 Issue: 1
Author(s): Shinya Kasai, Hideko Yamamoto, Etsuko Kamegaya, George R. Uhl, Ichiro Sora, Masahiko Watanabe and Kazutaka Ikeda
Affiliation:
Keywords: Knockout mice, μ opioid receptor, quantification, Western blot analysis, alcohol-dependent, chronic cocaine, downregulates MOP mRNA, immunohistochemistry, MOP binding, mRNA levels, MOP proteins
Abstract: Increasing evidence suggests that μ opioid receptor (MOP) expression is altered during the development of and withdrawal from substance dependence. Although anti-MOP antibodies have been hypothesized to be useful for estimating MOP expression levels, inconsistent MOP molecular weights (MWs) have been reported in studies using anti-MOP antibodies. In the present study, we generated a new anti-MOP antibody (N38) against the 1-38 amino acid sequence of the mouse MOP N-terminus and conducted Western blot analysis with wildtype and MOP knockout brain lysates to determine the MWs of intrinsic MOP. The N38 antibody detected migrating bands with relative MWs of 60-67 kDa in the plasma membrane fraction isolated from wildtype brain, but not from the MOP knockout brain. These migrating bands exhibited semi-linear density in the range of 3-30 μg membrane proteins/lane. The N38 antibody may be useful for quantitatively detecting MOP.
Export Options
About this article
Cite this article as:
Kasai Shinya, Yamamoto Hideko, Kamegaya Etsuko, R. Uhl George, Sora Ichiro, Watanabe Masahiko and Ikeda Kazutaka, Quantitative Detection of μ Opioid Receptor: Western Blot Analyses Using µ Opioid Receptor Knockout Mice, Current Neuropharmacology 2011; 9(1) . https://dx.doi.org/10.2174/157015911795016921
DOI https://dx.doi.org/10.2174/157015911795016921 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Comparison of the Effects of Dexamethasone and Ondansetron on the Reduction of Postoperative Nausea and Vomiting following Cesarean Section under Spinal Anesthesia
Current Reviews in Clinical and Experimental Pharmacology Carbon Nano Tubes: Novel Drug Delivery System in Amelioration of Alzheimer’s Disease
Combinatorial Chemistry & High Throughput Screening Bone Seeking Radiopharmaceuticals for Palliation of Pain in Cancer Patients with Osseous Metastases
Anti-Cancer Agents in Medicinal Chemistry Bioactive Compounds Containing Benzoxadiazole, Benzothiadiazole, Benzotriazole
Current Bioactive Compounds Cytochromes P450 in the Bioactivation of Chemicals
Current Topics in Medicinal Chemistry Conference Report (42nd Annual Meeting of the Italian Society of Neurology, 22-25 October 2011, Turin, Italy)
CNS & Neurological Disorders - Drug Targets Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder
Current Neuropharmacology Glycobiology of Neural Stem Cells
CNS & Neurological Disorders - Drug Targets Patent Selections
Recent Patents on Anti-Infective Drug Discovery Pharmacokinetic Considerations of Perinatal Antiretroviral Therapy
Current Drug Metabolism Meet Our Editorial Board Member
Current Psychiatry Reviews Nebulizable Cycloserine Loaded PLGA Nanoparticles: Formulation Design, in vitro Evaluation and Stability Studies
Current Nanomedicine A Review: G-Quadruplex’s Applications in Biological Target Detection and Drug Delivery
Current Topics in Medicinal Chemistry Phytochemicals and Antioxidants: An Evaluation in Understanding the Human Lifeline
Current Nutrition & Food Science Bioactivity of New μ and δ Opioid Peptides
Medicinal Chemistry Gender Differences in the Suicide Attempts of Adolescents in Emergency Departments: Focusing on Individuals with Autism Spectrum Disorder
Adolescent Psychiatry Post-stroke Depression Therapy: Where are we now?
Current Neurovascular Research Is Human Immunodeficiency Virus-Mediated Dementia an Autophagic Defect that Leads to Neurodegeneration?
CNS & Neurological Disorders - Drug Targets Mammalian Cytosolic Glutathione Transferases
Current Protein & Peptide Science Nutritional Support in Cancer
Current Nutrition & Food Science